Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results.
Maurice Stephan Michel
Consultant or Advisory Role - Bayer Vital Health Care
Honoraria - Bayer Vital Health Care
Walter Vervenne
No relevant relationships to disclose
Peter J. Goebell
No relevant relationships to disclose
Ludwig Fischer Von Weikersthal
No relevant relationships to disclose
Werner Freier
No relevant relationships to disclose
Maria De Santis
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Uwe Zimmermann
No relevant relationships to disclose
Monique M.E.M. Bos
No relevant relationships to disclose
Lutz Trojan
Honoraria - Bayer
Christian A. Lerchenmuller
No relevant relationships to disclose
Marcus Schenk
No relevant relationships to disclose
Michael D. Staehler
No relevant relationships to disclose
Anne Flörcken
Honoraria - Bayer Vital Health Care
Other Remuneration - Bayer Vital Health Care; Pfizer
Sascha Pahernik
No relevant relationships to disclose
Maartje Los
No relevant relationships to disclose
Cornelis Van Arkel
No relevant relationships to disclose
Silke Schirrmacher-Memmel
No relevant relationships to disclose
Christian Eichelberg
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Other Remuneration - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche